WeVote
Log In

Bill

Bill

SB 1214

stem cells; birth tissue; therapy

57th Legislature - Second Regular Session Introduced by Janae Shamp

Arizona authorizes collection and therapeutic use of stem cells from birth tissues like umbilical cord blood, expanding regenerative medicine options while requiring regulatory clarity on safety and efficacy.

Vetoed by Governor
0
WeVote Research Nonpartisan
Bill Summary · SB 1214

Legislative bill overview

SB 1214 permits the use of stem cells derived from birth tissues (such as umbilical cord blood, placenta, and amniotic fluid) for therapeutic purposes in Arizona. The bill establishes a regulatory framework allowing collection, processing, and application of these biological materials for medical treatment without the restrictions typically applied to embryonic stem cell research.

Why is this important

Stem cell therapies derived from birth tissues are considered less ethically controversial than embryonic stem cells while potentially offering treatment options for various degenerative diseases and injuries. This bill could position Arizona as a destination for regenerative medicine research and treatment, potentially attracting biotech investment and providing patients access to emerging therapies.

Potential points of contention

  • Regulatory oversight gaps: The bill's specificity regarding safety standards, quality control, and FDA coordination remains unclear from the title alone, raising questions about patient safety and legitimacy of treatments
  • Clinical efficacy claims: Birth tissue stem cell therapies remain largely investigational; the bill could enable marketing of unproven treatments as established medicine, risking patient exploitation
  • Funding and access equity: Clarification needed on whether these therapies will be covered by insurance or only available to wealthy patients, potentially creating healthcare inequality

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.